PLEKHG5 and hepatocellular carcinoma: In conclusion, we found that PLEKHG5 expression was increased in human HCC and was further increased in sorafenib-resistant HCC (Fig. 8) PLEKHG5-related drug-resistance effects were mediated through regulation of the Rac1/AKT/NF-κB signaling cascades.